Determinants for Use of GLP-1 Receptor Agonists in Canada

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001058
• Study ID:
  1000001058
• Official title and acronym:
  Determinants for Use of GLP-1 Receptor Agonists in Canada
• DARWIN EU® study:
  No
• Study countries:
  Canada
• Study description:
  Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications which are either authorized for managing hyperglycemia in patients with type 2 diabetes mellitus (T2DM) or for weight management under certain conditions in Canada. In recent years, there has been an increase in demand for these medications which led to a global shortage, affecting many countries including the European Union (EU) Member States and Canada. There have also been concerns about excessive off-label use for weight management in people without obesity or people with overweight who do not have weight related health problems, and this is intensifying the existing shortages with serious consequences for public health.; As part of a collaboration with the International Coalition of Medicine Regulatory Authorities (ICMRA), CNODES will replicate a study conducted by DARWIN EU (EUPAS1000000828). This study aims to describe characteristics of patients prescribed a GLP-1 RA and patterns of use between 2005 and 2025, including switching between substances and to other antidiabetic medications, as well as switching between selected brands.; The study will span over up to 10 years and will be conducted using routinely collected health data from 6 Canadian provinces. The primary analyses will be restricted to patients receiving GLP-1 RA prescriptions reimbursed through provincial public drug plans and the secondary analyses will be conducted using all available GLP-1 RA dispensations (in provinces with available data). We will estimate the monthly incidence and monthly point prevalence of prescriptions of GLP-1 RAs. We will characterize new users by the specified covariates. We will also describe the patterns of use including switching between substances and to other antidiabetics, as well as within-substance switching of strength.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Lady Davis Institute

University of British Columbia

University of Calgary, Calgary, Canada;
University of Manitoba, Winnipeg, Canada;
Dalhousie University, Halifax, Canada;
ICES, Toronto, Canada;
Saskatchewan Health Quality Council, Saskatoon, Canada

Networks

Canadian Network for Observational Drug Effect Studies (CNODES)

Canada

Study timelines

Date when funding contract was signed

Actual:16/03/2026

Study start date

Actual:16/03/2026

Date of final study report

Planned:14/05/2027

Sources of funding

Other

More details on funding

CNODES is a collaborating core network partner of CoLab, which is funded for query-related activity by Canada’s Drug Agency (CDA-AMC, grant number C222 360).

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable